Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Neurochemical Transmission: Sites of Drug Action01:26

Neurochemical Transmission: Sites of Drug Action

Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of Monoacylglycerol Lipase (MAGL) in Substance Use: A Systematic Review of Preclinical Studies.

Biological psychiatry·2026
Same author

PET imaging of FAAH in chronic Cannabis users: longitudinal assessment during short-term abstinence.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Autoradiography and preclinical PET studies with radiolabeled asyn-44 and ACI-12589 for imaging α-synuclein.

Journal of Parkinson's disease·2026
Same author

Tau-PET imaging and blood biomarkers reveal early tauopathy in special operations forces exposed to repetitive blast.

Brain communications·2026
Same author

Correction: Histamine H3 Receptor as a target for alcohol use disorder: challenging the predictability of animal models for clinical translation in drug development.

Translational psychiatry·2026
Same author

A repeat expansion in GOLGA8A is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions.

Nature genetics·2026

Related Experiment Video

Updated: Jun 29, 2026

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
08:49

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Published on: September 23, 2015

Brain serotonin transporter in human methamphetamine users.

Stephen J Kish1, Paul S Fitzmaurice, Isabelle Boileau

  • 1Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada.

Psychopharmacology
|October 9, 2008
PubMed
Summary
This summary is machine-generated.

Methamphetamine (MA) use may modestly damage brain serotonin neurones, particularly in the cerebral cortex. This study measured serotonin transporter (SERT) protein levels in chronic MA users, finding significant reductions in certain brain regions.

More Related Videos

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

Related Experiment Videos

Last Updated: Jun 29, 2026

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
08:49

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Published on: September 23, 2015

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

Area of Science:

  • Neuroscience
  • Toxicology
  • Psychiatry

Background:

  • Methamphetamine (MA) toxicity research often focuses on dopamine neuron damage.
  • Animal studies suggest MA also damages serotonin neurons, potentially explaining cognitive and behavioral issues in users.
  • Limited human data exists on MA's impact on the brain's serotonin system.

Purpose of the Study:

  • To investigate if chronic MA use decreases serotonin transporter (SERT) protein levels in the human brain.
  • To assess SERT levels as a marker for serotonin neuron integrity in MA users.

Main Methods:

  • Immunoblotting was used to measure SERT immunoreactivity.
  • Autopsied brain tissue from 16 chronic MA users and matched controls was analyzed.
  • MA users were confirmed positive for the drug in blood and brain tissue.

Main Results:

  • SERT levels showed non-significant decreases in subcortical regions (caudate, putamen, thalamus).
  • Significant decreases in SERT concentrations were observed in the orbitofrontal and occipital cortices.
  • A marked overlap in SERT levels between controls and MA users was noted in subcortical areas, unlike dopamine reduction.

Conclusions:

  • MA use may modestly damage brain serotonin neurons or reduce SERT expression, with greater impact in the cerebral cortex.
  • Reduced SERT in the orbitofrontal cortex aligns with its suspected role in MA-related behaviors.
  • Decreased brain SERT may explain why selective serotonin reuptake inhibitors can increase MA relapse risk.